The Human Cost of Respiratory Syncytial Virus (RSV)
For many parents, RSV is a term they only encounter in a doctor’s office. For Lynn Power, it is a lifelong memory of trauma. In 2023, her son Rian spent 10 days on a ventilator as medical teams fought to save his life.
The experience was more than just a medical emergency; it was a logistical nightmare. Power recalls the flashing lights of an ambulance transporting Rian from University Hospital Waterford to specialist care in Dublin. Even now, at two and a half years old, Rian continues to face health struggles, including lung injury and feeding issues resulting from his time on a ventilator.
“There’s no other word for watching a child being intubated. I can’t say enough excellent things about the care that he got in Waterford.” Lynn Power, parent
Rian’s story highlights a critical gap in pediatric care: the distance between the availability of life-saving preventative medicine and the actual administration of that medicine to the children who need it most.
The Preventative Shift: Nirsevimab and Monoclonal Antibodies
The medical community is moving toward a novel era of prevention. Rather than treating RSV after a child is already gasping for breath, the focus has shifted to monoclonal antibodies. Specifically, a treatment called nirsevimab, manufactured by Sanofi/AstraZeneca, is being used to protect infants via injection.
A pilot program running since 2024 has shown promising results. The Health Information and Quality Authority (Hiqa) recently confirmed that the program is safe and effective
, noting that it appears to have had a positive impact
on hospital staff who previously dealt with overwhelming seasonal pressure.
Though, the transition from a “pilot” to a “permanent” national program is stalled by a recurring conflict in modern medicine: the clash between clinical necessity and economic viability.
The Economic Tug-of-War: Clinical Need vs. Budgetary Reality
While doctors see a clear clinical victory, economists see a budgetary challenge. Hiqa has suggested that while the immunization is effective, it is too expensive at current prices. To be considered cost-effective, the agency suggests costs may need to be almost halved.
The financial stakes are significant. Hiqa noted a projected cost range of €15.6m to €58.5m over five years, depending on the implementation strategy. This creates a classic healthcare dilemma known as opportunity cost
.
According to health economist Brian Turner of University College University College Cork, the decision isn’t just about RSV. It is about whether that money is better spent on other critical areas, such as a new cancer drug or heart stents or homecare
.
Future Trends in Pediatric Immunization and Pricing
The battle over RSV pricing is a precursor to how future pediatric breakthroughs will be handled. Several trends are emerging that will shape the next decade of healthcare:
1. Value-Based Pricing Models
We are likely to see a shift toward value-based pricing, where the cost of a drug is tied to the actual outcomes it produces. If nirsevimab significantly reduces the number of children requiring expensive ICU transfers from cities like Cork, Galway, or Donegal, the “value” of the drug increases, potentially justifying a higher price point.
2. Increased Pressure on Pharmaceutical Negotiations
The tension between the HSE and pharmaceutical companies is not new. Previous breakdowns in talks regarding cystic fibrosis medication led to public protests in 2022. As more “orphan drugs” and specialized immunizations enter the market, the public and clinical pressure on the HSE to secure lower prices through aggressive negotiation will intensify.
3. Decentralization of Specialist Care
The trauma of transporting critically ill children across the country is a primary driver for the push toward prevention. Future trends suggest a move toward more localized high-dependency care to avoid the danger of having to drive all that distance up to an ICU bed
, as warned by Dr. Turlough Bolger, clinical director at Children’s Health Ireland.
The Role of Evidence in Policy Making
the decision to fund these programs rests with the HSE, guided by recommendations from the National Centre for Pharmacoeconomics (NCPE). Professor Michael Barry, the NCPE clinical director, emphasizes that these assessments are based strictly on science and clinical trials.
While the emotional weight of stories like Rian’s is immense, the institutional process remains focused on the relationship between price and outcome. The challenge for the future is integrating the human experience of “medical trauma” into the mathematical equations used to determine cost-effectiveness.
For more information on pediatric health trends, visit the HSE official portal or explore our related guides on healthcare innovation.
Frequently Asked Questions
It is a monoclonal antibody administered by injection to infants to prevent severe RSV infections.
Why is there a debate about its cost?
While safe and effective, health authorities like Hiqa argue the current price is too high to be cost-effective when compared to other health service needs.
How many children are affected by RSV annually?
Historically, an estimated 1,800 children were admitted to hospitals every winter in Ireland due to RSV.
Who makes the final decision on funding these vaccines?
The NCPE provides a scientific recommendation, but the final decision on reimbursement rests with the HSE.
Do you believe clinical effectiveness should always outweigh cost in pediatric care, or is “opportunity cost” a necessary reality for public health? Share your thoughts in the comments below or subscribe to our newsletter for more deep dives into healthcare policy.
